Announced details
Used by multiple major pharmaceutical companies (number of companies not disclosed)
FRONTEO was selected for a support program implemented by the Tokyo Metropolitan Government.
The entity implementing a support program aimed at promoting the rapid growth of mid-sized companies in Tokyo and revitalizing industries in Tokyo. Its location, representative, capital and year of establishment are not disclosed.
A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed)
Minato-ku, Tokyo (FRONTEO headquarters), Collaborative research center with Institute of Science Tokyo (location not disclosed), KIBIT AI Biology Lab (location not disclosed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Tokyo Metropolitan Government “Next Edge Tokyo” Official Website
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | Tokyo Metropolitan Government |
| Counterparty overview | The entity implementing a support program aimed at promoting the rapid growth of mid-sized companies in Tokyo and revitalizing industries in Tokyo. Its location, representative, capital and year of establishment are not disclosed. |
| Relationship with the Company | FRONTEO was selected for a support program implemented by the Tokyo Metropolitan Government. |
| Applicable area | AI drug discovery, Pharmaceutical Research and Development, Life Science |
| Registration number and expiry date | A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed) |
| Location | Minato-ku, Tokyo (FRONTEO headquarters), Collaborative research center with Institute of Science Tokyo (location not disclosed), KIBIT AI Biology Lab (location not disclosed) |
| Usage history | Used by multiple major pharmaceutical companies (number of companies not disclosed) |
| Source | Tokyo Metropolitan Government “Next Edge Tokyo” Official Website |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To address the need to discover highly novel drug discovery targets and improve the efficiency of research and development amid longer drug development timelines and rising research and development costs.